Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy

Abstract Aim Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Chemotherapy is the mainstay systemic therapy for PDAC, and chemoresistance is a major clinical problem leading to therapeutic failure. This study aimed to identify key differences in gene express...

Full description

Bibliographic Details
Main Authors: Sumit Sahni, Christopher Nahm, Mahsa S. Ahadi, Loretta Sioson, Sooin Byeon, Angela Chou, Sarah Maloney, Elizabeth Moon, Nick Pavlakis, Anthony J. Gill, Jaswinder Samra, Anubhav Mittal
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
biomarkers
chemotherapy response
gene expression analysis
neoadjuvant chemotherapy
pancreatic ductal adenocarcinoma
Online Access:https://doi.org/10.1002/cam4.6411

Internet

https://doi.org/10.1002/cam4.6411

Similar Items